Literature DB >> 15772142

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Johan W Mouton1, Michael N Dudley, Otto Cars, Hartmut Derendorf, George L Drusano.   

Abstract

Interest in the relationships between the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents has increased over recent years. Since the appearance 2 years ago of our first article describing terminology in PK/PD, the field has continued to expand rapidly, urgently requiring an update. This paper describes in a uniform manner the use of PK/PD expressions for antimicrobial agents, and their units.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772142     DOI： 10.1093/jac/dki079

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  141 in total

1.  Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

Authors:  B D Lacroix; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

2.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

Review 3.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Elizabeth B Hirsch; Kimberly R Ledesma; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.

Authors:  M Andraud; C Chauvin; P Sanders; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

7.  Optimizing the initial amikacin dosage in adults.

Authors:  Bryan P White; Ben Lomaestro; Manjunath P Pai
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

8.  Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.

Authors:  Ken Coleman; Premavathy Levasseur; Anne-Marie Girard; Monica Borgonovi; Christine Miossec; Henri Merdjan; George Drusano; David Shlaes; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

9.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

10.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.